• Home
  • About Us
  • Technology
  • Pipeline
  • Partnerships
  • News & Publications
HDT Bio

Reuters: Emcure wins dismissal of US lawsuit over COVID-19 vaccine trade secrets

Dec 5, 2023 | In the News

Click here to view...

Law360: Wash. Judge Nixes HDT’s $950M mRNA Vax Trade Secrets

Dec 4, 2023 | In the News

Click here to view...

Pharmaceutical Technology: HDT Bio navigates vaccine strategy in a changing Covid-19 landscape

Oct 24, 2023 | In the News

Click here to view...

PharmaVoice: Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine

Aug 14, 2023 | In the News

Click here to view...

The Bio Report: Addressing a Global Need with RNA Vaccines and Immunotherapies

Aug 2, 2023 | In the News

Click here to view...

Clinical Trials Arena: The tipping point of outsourcing: To build internally or seek external help?

Jul 25, 2023 | In the News

Click here to view...
« Older Entries
Next Entries »

Recent Posts

  • Providence Swedish Neuroscience Institute (PSNI) Reaches Milestone in Reducing Global Burden of Glioblastoma
  • A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
  • KING5 Seattle Healthlink Feature: Seattle-based group testing new immunotherapy approach to treat deadly form of brain cancer
  • HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial
  • FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow